LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
<!--StartFragment--> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Background: Imatinib has become first line therapy in c...
Saved in:
| Main Authors: | Michelina Santopietro, Giuseppina Loglisci, Roberto Latagliata, Corrado Girmenia, Massimo Breccia, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/8428 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01) -
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01) -
Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
by: Michiels S, et al.
Published: (2024-09-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)